Click on a filter below to refine your search. Remove filter to broaden your search.
Hint: If you don't want the words you enter to be searched for separately, use quotation marks to find people or exact phrases. See our Search Help section for more hints.
Tofacitinib 5mg tabs.
Pfizer announced that the FDA has approved Xeljanz (tofacitinib citrate) tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate.
Pfizer announced that the FDA has approved the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) to include additional patient-reported outcomes data in the label.
Pfizer announced that the FDA has approved a sNDA to update the current label of Xeljanz (tofacitinib citrate) tablets to include radiographic data from two Phase 3 studies, ORAL Scan and ORAL Start.
Pfizer announced results from OPT Compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
The FDA has accepted Pfizer's sNDA for review for an expanded indication for Xeljanz to include inhibition of progression of structural damage in the label. Xeljanz is a first in its class Janus Kinase inhibitor.
Enjoy the year in review of new drug products from 2013
Featured drug products: Adasuve, Adempas, Belviq, Breo Ellipta, Diclegis, Eliquis, Fetzima, Fulyzaq, Giazo, Invokana, Juxtapid, Kazano, Kynamro, Liptruzet, Nesina, Opsumit, Oseni, Oxtellar...
Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs).
This patient information fact sheet provides information on the definition, symptoms, causes, diagnostic tests, treatments and self-help measures for rheumatoid arthritis.
Dosing regimens of DMARDS and other immune modulators used in the treatment of arthritis.
This CME/CEU activity is designed to give clinicians a better understanding of the pharmacology, indications, contraindications, benefits/risk and clinical trials data of a broad spectrum of new agents and those that have been granted a new indication.